Zhizhuang Zhao to Male
This is a "connection" page, showing publications Zhizhuang Zhao has written about Male.
Connection Strength
0.239
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
Score: 0.059
-
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol. 2014 Jul 15; 193(2):477-84.
Score: 0.039
-
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol. 2014 Mar 19; 7:25.
Score: 0.039
-
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011 Jan 14; 4:4.
Score: 0.031
-
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007 Jan 01; 109(1):339-42.
Score: 0.023
-
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 04 06; 2(7):e90932.
Score: 0.012
-
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol. 2015 Apr; 94(4):717-9.
Score: 0.010
-
CD169? macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med. 2013 Apr; 19(4):429-36.
Score: 0.009
-
RBPJ mutations identified in two families affected by Adams-Oliver syndrome. Am J Hum Genet. 2012 Aug 10; 91(2):391-5.
Score: 0.009
-
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11):1058-68.
Score: 0.008